Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (OTCBB: OGEN) announced today that its Exclusive Channel Collaboration (ECC) with Intrexon Corporation, a synthetic biology company, has produced an exponential increase in the fermentation titer of the target compound MU1140 and the discovery of a promising new purification process for this product. This demonstrates significant progress toward the commercial production of its lead lantibiotic, MU1140, and delivers an important step in validating the lantibiotics platform targeting infectious diseases. Oragenics and Intrexon have been working together through the ECC to produce a pipeline of new lantibiotics that have been shown to be active against essentially all Gram-positive pathogens, including vancomycin-resistant enterococci (VRE), Clostridium difficile, methicillin-resistant Staphylococcus aureus (MRSA), as well as multi-drug resistant strains of Mycobacterium tuberculosis.